Recognition and management of pulmonary hypertension

Drugs

Volumn 56, Issue 6, 1998, Pages 989-1007

  Wanstall, Janet C ^a   Jeffery, Trina K ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CALCIUM ANTAGONIST; DILTIAZEM; ENDOTHELIN RECEPTOR ANTAGONIST; HEPARIN; NIFEDIPINE; NITRIC OXIDE; NITRIC OXIDE DONOR; POTASSIUM CHANNEL STIMULATING AGENT; PROSTACYCLIN; VASODILATOR AGENT; WARFARIN;

ARTICLE; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; ENDARTERECTOMY; GENE THERAPY; HEART LUNG TRANSPLANTATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LONG TERM CARE; LUNG TRANSPLANTATION; NEWBORN DISEASE; ORAL DRUG ADMINISTRATION; OXYGEN THERAPY; PROVOCATION TEST; PULMONARY HYPERTENSION; THROMBOCYTE AGGREGATION;

ANTICOAGULANTS; CALCIUM CHANNEL BLOCKERS; ENDARTERECTOMY; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; INFANT, NEWBORN; LUNG DISEASES, OBSTRUCTIVE; NITRIC OXIDE; OXYGEN; PERSISTENT FETAL CIRCULATION SYNDROME; VASODILATOR AGENTS;

EID: 0344178016     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199856060-00004     Document Type: Article

References (163)

1. Brown G. Pharmacologic treatment of primary and secondary pulmonary hypertension. Pharmacotherapy 1991; 11: 137-56
2. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987; 107: 216-23
3. Salvaterra CG, Rubin LJ. Investigation and management of pulmonary hypertension in chronic obstructive pulmonary disease. Am Rev Respir Dis 1993; 148: 1414-7
4. Dinh-Xuan AT. Disorders of endothelium-dependent relaxation in pulmonary disease. Circulation 1993; 87: V81-7
5. Loscalzo J. Endothelial dysfunction in pulmonary hypertension. N Engl J Med 1992; 327: 117-9
6. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327: 70-5
7. Oakley CM. Investigation and diagnosis of pulmonary hypertension in adults. In: Morice AH, editor. Clinical pulmonary hypertension. London: Portland Press, 1995: 81-113
8. Barst RJ. Diagnosis and treatment of pulmonary artery hypertension. Curr Opin Pediatr 1996; 8: 512-9
9. Moraes D, Loscalzo J. Pulmonary hypertension: newer concepts in diagnosis and management. Clin Cardiol 1997; 20: 676-82
10. Chaouat A, Weitzenblum E. Higenbottam T. The role of thrombosis in severe pulmonary hypertension. Eur Respir J 1996; 9: 356-63
11. Rich S, Kauffman E, Levy PS. The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81
12. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70: 580-7
13. Frank H, Mlczoch J, Huber K, et al. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 1997; 112: 714-21
14. Camerini F, Alberti E, Klugman S, et al. Primary pulmonary hypertension: effects of nifedipine. Br Heart J 1980; 44: 352-6
15. Rubin LJ, Nicod P, Hisslis LD, et al. Treatment of primary pulmonary hypertension with nifedipine: a hemodynamic and scintigraphic evaluation. Ann Intern Med 1983; 99: 433-8
16. De Feyter PJ, Kerkkamp HJJ, de Jong JP. Sustained beneficial effect of nifedipine in primary pulmonary hypertension. Am Heart J 1983; 105: 333-4
17. Rich S. Calcium channel blockers for the treatment of primary pulmonary hypertension. Eur Respir Rev 1995; 29: 252-4
18. Rich S, Kauffman E. High dose titration of calcium channel blocking agents for primary pulmonary hypertension: guidelines for short-term drug testing. J Am Coll Cardiol 1991; 18: 1323-7
19. Gassner A, Sommer G, Fridrich L, et al. Differential therapy with calcium antagonists in pulmonary hypertension secondary to COPD. Chest 1990; 98: 829-34
20. Alpert MA, Pressly TA, Mukerji V, et al. Acute and long-term effects of nifedipine on pulmonary and systemic hemodynamics in patients with pulmonary hypertension associated with diffuse systemic sclerosis, the CREST syndrome and mixed connective tissue disease. Am J Cardiol 1991; 68: 1687-91
21. Nootens M, Kauffman E, Rich S. Short-term effectiveness of nifedipine in secondary pulmonary hypertension. Am J Cardiol 1993; 71: 1475-6
22. Kalra L, Bone MF. Effect of nifedipine on physiologic shunting and oxygenation in chronic obstructive pulmonary disease. Am J Med 1993; 94: 419-23
23. Rich S, Brundage BH, Levy PS. The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension. Circulation 1985; 71: 1191-6
24. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-7
25. Malik AS, Warshafsky S, Lehrman S, Meta-analysis of the long-term effect of nifedipine for pulmonary hypertension. Arch Intern Med 1997; 157: 621-5
26. Sajkov D, Wang T, Frith PA. et al. A comparison of two long-acting vasoselective calcium antagonists in pulmonary hypertension secondary to COPD. Chest 1997; 111: 1622-30
27. 1 for severe idiopathic pulmonary artery hypertension [letter]. Lancet 1980; 1: 1083
28. Rubin LJ. Groves BM, Reeves JT. et al. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation 1982; 66: 334-8
29. Badesch DB. Clinical trials in pulmonary hypertension. Annu Rev Med 1997; 48: 399-408
30. Hinderliter AL, Willis PW, Barst RJ, et al. Effects of long-term infusion of proslacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Circulation 1997; 95: 1479-86
31. Magnani B, Galie N. Prostacyclin in primary pulmonary hypertension. Eur Heart J 1996: 17: 18-24
32. Higenbottam TW, Butt AY, Dinh-Xuan AT. et al. Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. Heart 1998; 79: 175-9
33. Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994; 121: 409-15
34. Barst RJ, Rubin LJ, Long W, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) wilh conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296-301
35. McLaughlin VV, Genthner DE, Panella MM, et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998; 338: 273-7
36. Keogh A, Macdonald P, Glanville A, et al. Ambulatory prostacyclin therapy for severe primary pulmonary hypertension: a bridge to heart-lung transplantation [abstract]. Aust N Z J Med 1991; 21: 510
37. 2) on survival in moderate and severe pulmonary hypertension [abstract]. Am J Respir Crit Care Med 1994; 149: A748
38. Higenbottam TW, Spiegelhalter D, Scott JP, et al. Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. Br Heart J 1993; 70: 366-70
39. Shapiro SM, Oudiz RJ, Cao T, et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997; 30: 343-9
40. Eronen M, Pohjavuori M, Andersson S, et al. Prostacyclin treatment for persistent pulmonary hypertension of the newborn. Pediatr Cardiol 1997: 18: 3-7
41. 1 and epoprostenol (prostacyclin) in infants after heart surgery. Br Heart J 1991; 66: 175-8
42. Schranz D, Zepp F, Iverson S, et al. Effects of tolazoline and prostacyclin on pulmonary hypertension in infants after cardiac surgery. Crit Care Med 1992; 20: 1243-9
43. Radermacher P, Santak B, Wust HJ, et al. Prostacyclin for the treatment of pulmonary hypertension in the adult respiratory distress syndrome: effects on pulmonary capillary pressure and ventilation-perfusion distributions. Anesthesiol 1990; 72: 238-44
44. de la Mata J, Gomez-Sanchez MA, Aranzana M, et al. Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases. Arthritis Rheum 1994; 37: 1528-33
45. Menon N, McAlpine L, Peacock AJ, et al. The acute effects of prostacyclin on pulmonary hemodynamics in patients with pulmonary hypertension secondary to systemic sclerosis. Arthritis Rheum 1998; 41: 466-9
46. Archer SL, Mike D, Crow J, et al. A placebo-controlled trial of prostacyclin in acute respiratory failure in COPD. Chest 1996; 109: 750-5
47. Jones K. Prostacyclin. In: Peacock AJ, editor. Pulmonary circulation: a handbook for clinicians. London: Chapman & Hall Medical, 1996; 115-22
48. Peacock AJ. Treatment of pulmonary hypertension. Drugs Today 1995; 31: 201-11
49. Walmrath D, Schneider T, Pilch J, et al. Aerosolised prostacyclin in adult respiratory distress syndrome. Lancet 1993; 342: 961-2
50. Pappert D, Busch T, Gerlach H, et al. Aerosolized prostacyclin versus inhaled nitric oxide in children with severe acute respiratory distress syndrome. Anesthesiol 1995; 82: 1507-11
51. Zwissler B, Rank N, Jaenicke U, et al. Selective pulmonary vasodilation by inhaled prostacyclin in a newborn with congenital heart disease and cardiopulmonary bypass. Anesthesiology 1995; 82: 1512-6
52. Haraldsson A, Kieler-Jensen N, Ricksten SE. Inhaled prostacyclin for treatment of pulmonary hypertension after cardiac surgery or heart transplanlation: a pharmacodynamic study. J Cardiothorac Vasc Anesthes 1996; 10: 864-8
53. Olschewski H, Walmrath D, Schermuly R, et al. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996: 124: 820-4
54. Webb SAR. Stott S, van Heerden PV. The use ot inhaled aerosolized prostacyclin (IAP) in the treatment of pulmonary hypertension secondary to pulmonary embolism. Intensive Care Med 1996; 22: 353-5
55. Mikhail G, Gibbs JSR, Richardson M, et al. An evaluation of nebulized prostacyclin in patients with primary and secondary pulmonary hypertension. Eur Heart J 1997; 18: 1499-504
56. 2 analogue, beraprost, in primary and secondary pulmonary hypertension. Am J Cardiol 1996; 78: 244-7
57. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991; 338: 1173-4
58. Adatia I, Wessel DL. Therapeutic use of inhaled nitric oxide. Curr Opin Pediatr 1994; 6: 583-90
59. Palmer RM, Ferrige AG, Moncada S, Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-6
60. Cremona G, Wood AM, Hall LW, et al. Effect of inhibitors of nitric oxide release and action on vascular tone in isolated lungs ol pig, sheep, dog and man. J Physiol 1994; 481: 185-95
61. Davidson D. Nitric oxide from bench to bedside: a perinatal perspective: part II. Int J Obstet Anesth 1996; 5: 244-53
62. Brett SJ, Gibbs JSR, Pepper JR, et al. Impairment of endothelium-dependent pulmonary vasodilation in patients with primary pulmonary hypertension. Thorax 1996; 51: 89-91
63. Dollberg S, Warner BW, Myatt L. Urinary nitrite and nitrate concentrations in patients with idiopathic persistent pulmonary hypertension of the newborn and effect of extracorporeal membrane oxygenation. Pediatr Res 1995; 37: 31-4
64. Kharitonov SA, Cailes JB, Black CM, et al. Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension. Thorax 1997; 52: 1051-5
65. Wessel DL, Adatia I, Giglia TM, et al. Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass. Circulation 1993; 88: 2128-38
66. Cornfield DN, Abman SH. Inhalational nitric oxide in pulmonary parenchymal and vascular disease. J Lab Clin Med 1996; 127: 530-9
67. Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. New Engl J Med 1997; 336: 597-604
68. Davidson D, Barefield ES, Kattwinkel J, et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter sludy. The I-NO/PPHN study group. Pediatrics 1998; 101: 325-34
69. Wessel DL, Adatia I, Van Marter LJ, et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn [abstract E7]. Pediatrics 1997; 100: 888
70. Kinsella JP, Abman SH. Controversies in the use of inhaled nitric oxide therapy in the newborn. Clin Perinatol 1998; 25: 203-17
71. Kinsella JP, Truog WE, Walsh WF. et al. Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. J Pediatrics 1997; 131: 55-62
72. Goldman AP, Tasker RC, Haworth SG, et al. Four patterns of response to inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics 1996; 98: 706-13
73. Rosenberg AA, Kennaugh JM, Moreland SG, et al. Longitudinal follow-up of a cohort of newborn infants treated with inhaled nitric oxide for persistent pulmonary hypertension. J Pediatr 1997; 131: 70-5
74. Tang SF, Miller OI. Low-dose inhaled nitric oxide for neonates with pulmonary hypertension. J Paediatr Child Health 1996; 32: 419-23
75. Rossaint R, Falke KJ, Lopez F, et al. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993; 328: 399-405
76. Gerlach H, Rossaint R, Pappert D, et al. Time-course and dose-response of nitric oxide inhalation for systemic oxygenation and pulmonary hypertension in patients with adult respiratory distress syndrome. Eur J Clin Invest 1993; 23: 499-502
77. Dellinger RP, Zimmerman JL, Taylor RW, et al. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled nitric oxide in ARDS study group. Crit Care Med 1998; 26: 15-23
78. Manktelow C, Bigatello LM, Hess D, et al. Physiologic determinants of the response to inhaled nitric oxide in patients with acute respiratory distress syndrome. Anesthesiology 1997; 87: 297-307
79. Treggiari-Venzi M, Ricou B, Romand JA, et al. The response to repeated nitric oxide inhalation is inconsistent in patients with acute respiratory distress syndrome. Anesthesiology 1998; 88: 634-41
80. Payen D. Is nitric oxide inhalation a 'cosmetic' therapy in acute respiratory distress syndrome? Am J Respir Crit Care Med 1998; 157: 1361-2
81. Roger N, Barbera JA, Roca J, et al. Nitric oxide inhalation during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 156: 800-6
82. Beghetli M, Habre W, Friedli B, et al. Continuous low dose inhaled nitric oxide for treatment of severe pulmonary hypertension after cardiac surgery in paediatric patients. Br Heart J 1995; 73: 65-8
83. Goldman AP, Delius RE, Deanfield JE, et al. Nitric oxide is superior to prostacyclin for pulmonary hypertension alter cardiac operations. Ann Thorac Surg 1995; 60: 300-6
84. Adatia I, Lillehei C, Arnold JH, et al. Inhaled nitric oxide in the treatment of postoperative graft dysfunction after lung transplantation. Ann Thorac Surg 1994; 57: 1311-8
85. Journois D, Pouard P, Mauriat P, et al. Inhaled nitric oxide as a therapy for pulmonary hypertension after operations tor congenital heart defects. J Thorac Cardiovasc Surg 1994; 107: 1129-35
86. Shah AS, Smerling AJ, Quaegebeur JM, et al. Nitric oxide treatment for pulmonary hypertension after neonatal cardiac operation. Ann Thorac Surg 1995; 60: 1791-3
87. Finer NN, Etches PC, Kamstra B, et al. Inhaled nitric oxide in infants referred for extracorporeal membrane oxygenation: dose response. J Pediatr 1994; 124: 302-8
88. Turanlahti MI, Laitinen PO, Sarna SJ, et al. Nitric oxide, oxygen, and prostacyclin in children with pulmonary hypertension. Heart 1998; 79: 169-74
89. Mariani G, Barefield ES, Carlo WA. The role of nitric oxide in the treatment of neonatal pulmonary hypertension. Curr Opin Pediatr 1996; 8: 118-25
90. Goldman AP, Rees PG, Macrae DJ. Is it time to consider domicillary nitric oxide? Lancet 1995; 345. 199-200
91. 1 for treatment of acute lung injury in severe multiple organ failure. Anesth Analg 1998; 86; 753-8
92. 1 and nitric oxide inhalation in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1998; 157: 1743-7
93. 1 in patients with pulmonary hypertension after mitral valve replacement and with adult respiratory distress syndrome. Anesth Analg 1997; 85: 507-13
94. Morgan JM, McCormack DG. Griffiths MJD, et al. Adenosine as a vasodilator in primary pulmonary hypertension. Circulation 1991; 84: 1145-9
95. Nootens M, Schrader B, Kauffman E, et al. Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension. Chest 1995; 107: 54-7
96. Schrader BJ, Inbar S, Kaufmann L, et al. Comparison of the effects of adenosine and nifedipine in pulmonary hypertension. J Am Coll Cardiol 1992; 19: 1060-4
97. Fullerton DA, Jones SD, Grover FL, et al. Adenosine effectively controls pulmonary hypertension after cardiac operations. Ann Thorac Surg 1996; 61: 1118-24
98. Fullerton DA, Jaggers J, Jones SD, et al. Adenosine for refractory pulmonary hypertension. Ann Thorac Surg 1996; 62: 874-7
99. Inbar S, Schrader BJ, Kauffman E, et al. Effects of adenosine in combination with calcium channel blockers in patients with primary pulmonary hypertension. J Am Coll Cardiol 1993; 21:413-8
100. Vaz Fragoso CA, Miller MA. Review of the clinical efficacy of theophylline in the treatment of chronic obstructive pulmonary disease. Am Rev Respir Dis 1993; 147: S40-7
101. Rabe KF, Magnussen H, Dent G. Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants. Eur Respir J 1995; 8: 637-42
102. Leeman M, Lejeune P, Melot C, et al. Reduction in pulmonary hypertension and in airway resistance by enoximone (MDL 17043) in decompensated COPD. Chest 1987; 91: 662-6
103. Nenci GG, Berrettini M, Todisco T. et al. Effects of dipyridamole on the hypoxemic pulmonary hypertension of patients with chronic obstructive pulmonary disease. Respiration 1988; 53: 13-9
104. Feneck R, Sherry K, Withington S, et al. Comparison of milrinone and dobutamine in pulmonary hypertensive patients following cardiac surgery [abstract]. Br J Anaesth 1995; 74 Suppl. 2: 6
105. Boomers OW, Duncan F, Feneck RO, et al. Comparison of the haemodynamic effects of milrinone and GTN on pulmonary hypertension following mitral valve surgery [abstract]. Br J Anaesth 1995; 74 Suppl. 2: 6
106. Jenkins IR, Dolman J, O'Connor JP, et al. Amrinone versus dobutamine in cardiac surgical patients with severe pulmonary hypertension after cardiopulmonary bypass: a prospective. randomized double-blind trial. Anaesth Intensive Care 1997; 25: 245-9
107. Patole SK, Finer NN. Experimental and clinical effects of magnesium infusion in the treatment of neonatal pulmonary hypertension. Magnes Res 1995; 8: 373-88
108. Abu-Osba YK. Galal O, Manasra K, et al. Treatment of severe persistent pulmonary hypertension of the newborn with magnesium sulphate. Arch Dis Child 1992; 67: 31-5
109. Tolsa JF, Cotting J, Sekarski N, et al. Magnesium sulphate as an alternative and sale treament for severe persistent pulmonary hypertension of the newborn. Arch Dis Child 1995: 72: F184-7
110. 2 in the evaluation and treatment of children with pulmonary hypertension secondary to congenital heart defects. Circulation 1994; 90: 1287-93
111. Parida SK, Baker S, Kuhn R, et al. Endotracheal tolazoline administration in neonates with persistent pulmonary hypertension. J Permatol 1997; 17: 461-4
112. Welch JC, Bridson JM. Gibbs JL. Endotracheal tolazoline for severe persistent pulmonary hypertension of the newborn. Br Heart J 1995; 73. 99-100
113. Lewczuk J, Sobkowicz-Wozniak B, Piszko P, et al. Long-term prazosin therapy for COPD pulmonary hypertension. Chest 1992; 102: 635-6
114. Spah F, Kottman R, Schmidt U. Effects of single intravenous administration of urapidil and diltiazem in patients with non-fixed pulmonary hypertension secondary to chronic obstructive lung diseasc. J Cardiovasc Pharmacol 1994; 23: 517-24
115. Radermacher P, Huet Y, Pluskwa F, et al. Comparison of ketanserin and sodium nitroprusside in patients with severe ARDS. Anesthesiology 1988; 08: 152-7
116. van der Starre PJ, Feld RJ, Reneman RS. Ketanserin in the treatment of pulmonary hypertension after valvular surgery; a comparison with sodium nitroprusside. Crit Care Med 1989; 17: 613-8
117. Domenighetti G, Leuenberger P, Feihl F. Haemodynamic effects of ketanserin either alone or with oxygen in COPD patients with secondary pulmonary hypertension. Monald Arch Chest Dis 1997; 52: 429-33
118. 1-like receptor-mediated vasoconstriction in human pulmonary artery. Br J Pharmacol 1996; 119: 277-82
119. Waller DG. ACE inhibitors. In: Peacock AJ, ed. Pulmonary circulation: a handbook for clinicians. London: Chapman & Hall, 1996: 141-53
120. Pison CM, Wolf JE, Levy PA, et al. Effects of captopril combined with oxygen therpay at rest and on exercise in patients with chronic bronchitis and pulmonary hypertension. Respiration 1991; 58: 9-14
121. Alpert MA, Pressly TA, Mukerji V, et al. Short- and long-term hemodynamic effects of captopril in patients with pulmonary hypertension and selected connective tissue disease. Chest 1992; 102: 1407-12
122. Niazova ZA, Batyraliev TA, Aikimbaev KS, et al. High-altitude pulmonary hypertension: effects of captopril on pulmonary and systemic arterial pressures. J Hum Hypertens 1996; 10 Suppl. 3: S141-S142
123. Morrell NW, Morris KG, Stenmark KR. Role of angiotensin-converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension. Am J Physiol 1995; 269: H1186-94
124. Kiely DG, Cargill RI, Wheeldon NM, et al. Haemodynamic and endocrine effects of type I angiotensin II receptor blockade in patients with hypoxaemic cor-pulmonale. Cardiovasc Res 1997; 33: 201-8
125. Eisen HJ, Pina IL, Mather P, et al. Improvement in pulmonary hypertension refractory to standard vasodilators using the angtiotensin II receptor antagonist losartan in patients with severe congestive heart failure (abstract). Circulation 1996; 94 Suppl.: 289
126. Levine BE, Bigelow DB, Hamstra RD, et al. The role of long-term continuous oxygen administration in patients with chronic airway obstruction with hypoxemia. Ann Intern Med 1967; 66: 6.39-50
127. Abraham AS, Cole RB, Bishop JM. Reversal of pulmonary hypertension by prolonged oxygen administration to patients with chronic bronchitis. Circ Res 1968; 23: 147-57
128. Nocturnal Oxygen Therapy Trial Group. Continuous nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease. Ann Intern Med 1980; 93: 391-8
129. Weitzenblum E,. Sautegeau A, Ehrhart M, et al. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1985; 131: 493-8
130. Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulnionale complicating chronic bronchitis and emphysema. Lancet 1981; 1: 681-6
131. Zielinski J, Tobiasz M, Hawrylkiewicz I, et al. Effects of long-term oxygen therapy on pulmonary hemodynamics in COPD patients: a 6-year prospective study. Chest 1998; 113: 65-70
132. Dean NC, Brown JK, Himelman RB, et al. Oxygen may improve dyspnea and endurance in patients with chronic obstructive pulmonary disease and only mild hypoxemia. Am Rev Respir Dis 1992; 146: 941-5
133. Wright JL, Petty T, Thurlbeck WM. Analysis of the structure of the muscular pulmonary arteries in patients with pulmonary hypertension and COPD: National Institutes of Health nocturnal oxygen therapy trial. Lung 1992; 170: 109-24
134. Reitz BA, Wallwork JL, Hunt SA, et al. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med 1982; 306: 557-64
135. Bando K, Armitage JM, Paradis IL, et al. Indications for and results of single, bilateral, and heart-lung transplantation for pulmonary hypertension. J Thorac Cardiovasc Surg 1994; 108: 1056-65
136. Corris PA. Lung transplantation for pulmonary vascular disease. In; Morice AH, editor. Clinical pulmonary hypertension. London: Portland Press, 1995; 245-59
137. Registry of the International Society for Heart and Lung Transplantation: Eleventh Official Report 1994. J Heart Lung Transplant 1994; 13: 561-70
138. Australian and New Zealand Cardiothoracic Transplant Registry. 6th Annual Report, 1984-1997; 1998
139. Rich S. Medical treatment of primary pulmonary hypertension: a bridge to transplantation. Am J Cardiol 1995; 75: 63A-6A
140. Kneussl MP, Lang IM, Brenot FP. Medical management of primary pulmonary hypertension. Eur Respir J 1996; 9: 2401-9
141. Nakagawa TA, Morris A, Gomez RJ, et al. Dose response to inhaled nitric oxide in pediatric patients with pulmonary hypertension and acute respiratory distress syndrome. J Pediatr 1997; 131: 63-9
142. Abman SH. Inhaled nitric oxide therapy of severe neonatal pulmonary hypertension. Acta Anaesthes Scand 1995; 65-8
143. Dev D, Howard P. Pulmonary hypertension in chronic obstructive pulmonary disease. In: Morice AH. editor. Clinical pulmonary hypertension. London: Portland Press, 1995: 115-28
144. Yoshida M, Taguchi O, Gabazza EC, et al. Combined inhalation of nitric oxide and oxygen in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 155: 526-9
145. McAlpine LG, Peacock AJ. Thromboembolic pulmonary hypertension. In: Morice AH, editor. Clinical pulmonary hypertension. London: Portland Press, 1995: 129-51
146. Moser KM, Fedullo PF. Acute and chronic pulmonary thromhoembolism. In: Peacock AJ. editor. Pulmonary circulation: a handbook for clinicians. London: Chapman & Hall Medical, 1996: 391-422
147. Vongpatanasin W, Brickner ME. Hillis LD, et al. The Eisenmenger syndrome in adults. Ann Intern Med 1998; 128: 745-55
148. Cockrill BA. The use of nitric oxide in primary pulmonary hypertension. Respir Care Clin North Am 1997; 3: 505-19
149. Ivy DD, Griebel JL, Kinsella JP, et al. Acute hemodynamic effects of pulsed delivery of low flow nasal nitric oxide in children with pulmonary hypertension. J Pediatr 1998; 133: 453-6
150. Weis CM, Wolfson MR, Shaffer TH. Liquid assisted ventilation: physiology and clinical application. Ann Med 1997; 29: 509-17
151. Wilcox DT, Glick PL, Karamanoukian HL, et al. Partial liquid ventilation and nitric oxide in congenital diaphragmatic hernia. J Pediatr Surg 1997; 32: 1211-5
152. Zobel G, Urlesberger B, Dacar D, et al. Partial liquid ventilation combined with inhaled nitric oxide in acute respiratory failure with pulmonary hypertension in piglets. Pediatr Res 1997; 41: 172-7
153. Ichida F, Uese K, Tsubata A, et al. Additive effect of beraprost on pulmonary vasodilation by inhaled nitric oxide in children with pulmonary hypertension. Am J Cardiol 1997; 80: 662-4
154. Ziegler JW, Ivy DD, Fox JJ, et al. Dipyridamole, a cGMP phosphodiesterase inhihitor, causes pulmonary vasodilation in the ovine fetus. Am J Physiol 1995; 269: H473-9
155. Ichinose F, Adrie C, Hurford WE, et al. Selective pulmonary vasodilation induced hy aerosolized zaprinast. Anesthesiology 1998; 88: 410-6
156. Oka M, Morris KG. McMurtry IF. NIP-121 is more effective than nifedipine in acutely reversing chronic pulmonary hypertension. J Appl Physiol 1993; 75: 1075-80
157. Wanstall JC. The pulmonary vasodilator properties of potassium channel opening drugs. Gen Pharmacol 1996; 27: 599-605
158. Chen SJ, Chen YF, Meng QC, et al. Endothelin-receptor antagonist hosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 1995; 79: 2122-31
159. Hill NS, Warhurton RR, Pietras L, et al. Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats. J Appl Physiol 1997; 83: 1209-15
160. Hampl V, Tristani-Firouzi M, Hutsell TC, et al. Nebulized nitric oxide/nucleophile adduct reduces chronic pulmonary hypertension. Cardiovasc Res 1996; 31: 55-62
161. Keefer LK, Nims RW, Davies KM, et al. 'NONOates' (l-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: convenient nitric oxide dosage forms. Methods Enzymol 1996; 268: 281-93
162. Curiel DT, Pilewski JM, Albeda SM. Gene therapy approaches for inherited and acquired lung diseases. Am J Respir Cell Mol Biol 1996; 14: 1-18
163. Janssens SP, Bloch KD, Nong Z, et al. Adenoviral-mediated transfer of the human endothelial nitric oxide synthase gene reduces acute hypoxic pulmonary vasoconstriction in rats. J Clin Invest 1996; 98: 317-24